← Back to Search

Device

Tumor Treating Fields Therapy for Small Cell Lung Cancer

Phase 2

Waitlist Available

Led By Timur Mitin, MD

Research Sponsored by OHSU Knight Cancer Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up death or last follow up following start of ttfields therapy, whichever comes first (assessed at 6, 12, 24, 36 and 60 months)

Awards & highlights

Study Summary

This trial will study a new cancer treatment called Optune-Tumor Treating Fields (TTFields). The treatment will be given to people with small cell lung cancer that has spread to the brain, in order to try to prevent the cancer from growing.

Eligible Conditions

Small Cell Lung Cancer
Lung Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ death or last follow up following start of ttfields therapy, whichever comes first (assessed at 6, 12, 24, 36 and 60 months)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~death or last follow up following start of ttfields therapy, whichever comes first (assessed at 6, 12, 24, 36 and 60 months)

This trial's timeline: 3 weeks for screening, Varies for treatment, and death or last follow up following start of ttfields therapy, whichever comes first (assessed at 6, 12, 24, 36 and 60 months) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence of Small Cell Lung Cancer (SCLC) Brain Metastases at 6 Months

Secondary outcome measures

Change in Quality of Life Over Time: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30)

Incidence of Cognitive Adverse Events (AEs) Using Mini Mental State Exam (MMSE)

Incidence of SCLC Brain Metastases

+3 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Prevention (TTFields therapy, questionnaire)Experimental Treatment2 Interventions

Patients undergo TTFields therapy over 18-24 hours daily. Cycles repeat every 4 weeks for 12 months in the absence of disease progression or unacceptable toxicity.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Tumor Treating Fields Therapy

2018

Completed Early Phase 1

~30

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

OHSU Knight Cancer InstituteLead Sponsor

230 Previous Clinical Trials

2,090,723 Total Patients Enrolled

NovoCure Ltd.Industry Sponsor

57 Previous Clinical Trials

4,710 Total Patients Enrolled

Oregon Health and Science UniversityOTHER

973 Previous Clinical Trials

6,846,026 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How reliable is Tumor Treating Fields Therapy in providing a secure treatment for individuals?

"Tumor Treating Fields Therapy has been evaluated in a Phase 2 clinical trial, suggesting that while there is evidence of its safety profile, the efficacy remains unknown. Our team at Power thus assigned it a rating of 2 on our scale from 1 to 3."

Answered by AI

How many participants are eligible for inclusion in this research project?

"Affirmative. In accordance with the information on clinicaltrials.gov, this medical trial is currently seeking participants and was initially published on June 11th 2019; it has since been updated as recently as August 2nd 2022. The study requires 106 patients enrolled at 3 different locations."

Answered by AI

Is this experiment open to new enrollees?

"Affirmative, according to the clinicaltrials.gov entry this trial is still open for enrolment. It was originally posted on June 11th 2019 and most recently adjusted on August 2nd 2022. This research requires 106 participants from 3 distinct sites."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung Cancer

Timur Mitin 2019. "Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03995667.